QUESTIONS / ANSWERED
PT-141 FAQ
Direct answers on mechanism, receptors, the approved dose, side effects, and the central-versus-peripheral distinction. Cited where the claim is quantitative.
What does the PT-141 peptide do?
PT-141, a synthetic alpha-MSH analogue, switches on melanocortin receptors (MC3R/MC4R) found mostly in the brain. Systemic dosing produced erections in rats and primates and fired hypothalamic neurons (raised c-Fos), and produced dose-dependent erectile activity in men with erectile dysfunction in early studies [1]. Its approved effect is raising sexual desire in women with HSDD [3].
How does PT-141 work?
It works centrally, in the brain. PT-141 activates MC4R (and MC3R) in hypothalamic circuits such as the medial preoptic area, engaging dopamine pathways tied to sexual desire [1][5]. Unlike PDE-5 inhibitors, which act on blood vessels, it acts on the neural circuitry of desire — it is a brain drug, not a blood-flow drug [10].
What receptors does PT-141 act on?
Chiefly the melanocortin 4 receptor (MC4R), with MC3R as a secondary central target — both concentrated in the brain [1]. A peripheral receptor, MC1R in skin, is also activated, which explains the hyperpigmentation seen with repeated frequent dosing [7]. MC4R's presence in appetite circuits underlies the weight effects seen in high-frequency research dosing [9].
Does PT-141 work through the brain or through blood flow?
Through the brain. PT-141 acts centrally on hypothalamic and preoptic neurons that govern sexual motivation, not on vascular smooth muscle [10]. A human fMRI study showed MC4R agonism increased desire for up to 24 hours and altered brain processing of erotic stimuli — a central signal, not a vascular one [5]. PDE-5 inhibitors are the blood-flow class; PT-141 is not one [10].
What is a melanocortin receptor agonist?
A molecule that binds and switches on a melanocortin receptor — one of five G-protein-coupled receptors (MC1R-MC5R) that respond to natural signals like alpha-MSH [1][12]. PT-141 is a synthetic melanocortin receptor agonist selective for the central MC4R and MC3R subtypes, which is why it acts on desire rather than blood flow [1].
Does PT-141 increase testosterone?
No. PT-141 does not act through the HPG axis (the hormone loop controlling testosterone) and does not directly raise testosterone [9]. It is a melanocortin receptor agonist that works on brain desire circuits, a separate system entirely [1]. The belief that it boosts testosterone is a common misconception about its mechanism [9].
How is PT-141 different from PDE-5 inhibitors?
Mechanism and site of action. PDE-5 inhibitors act peripherally on vascular smooth muscle to improve blood flow. PT-141 acts centrally, on hypothalamic and preoptic neurons that govern sexual desire, and does not touch vascular smooth muscle [10]. One targets blood flow; the other targets the brain's desire circuitry [1][10].
Why does PT-141 cause nausea?
Nausea is the most common adverse effect — about 40% over long-term use — and is the principal tolerability issue and a driver of discontinuation [4]. It is consistent with the peptide's central melanocortin action; the brain pathways it engages overlap circuits involved in nausea. It is the leading cost of the desire benefit in the trial record [3][4].
Does PT-141 cause skin darkening or hyperpigmentation?
It can with repeated frequent dosing. Hyperpigmentation of the face, gums, and breasts is reported and attributed to activation of MC1R, the melanocortin receptor in skin melanocytes [7]. This is a peripheral effect, separate from the central MC4R action that drives desire [1][7].
Does PT-141 cause weight loss?
Weight and caloric-intake effects appeared in high-frequency Phase 1 research dosing, because MC4R also sits in appetite circuits [9]. This is a pharmacological consideration, not an approved or proven weight-loss use. The central melanocortin system is studied as a metabolic target, but bremelanotide is approved only for HSDD in women, not for weight [8][9].
What is PT-141?
PT-141 is bremelanotide, a synthetic cyclic heptapeptide and melanocortin (MC4R/MC3R) receptor agonist modeled on alpha-MSH [1][12]. It acts centrally to drive sexual desire and is FDA-approved (2019) for HSDD in premenopausal women [7]. Molecular weight ~1025.2 Da; CAS 189691-06-3.
What is PT-141 peptide?
The PT-141 peptide is a seven-amino-acid ring (cyclic heptapeptide), sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, formula C50H68N14O10 [1]. The ring makes it more stable than a linear peptide [7]. It is a melanocortin receptor agonist that activates central MC4R/MC3R to influence sexual desire [1].
What is PT-141 used for?
Its one approved use is treating acquired, generalized HSDD (distressing low sexual desire) in premenopausal women [7]. It is not approved for men, postmenopausal women, performance, or weight. Off-label and investigational research exists in men with erectile dysfunction, but did not lead to approval [13].
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the development code; bremelanotide is the international nonproprietary name (INN) for the same melanocortin receptor agonist [7][14]. The approved injectable drug and the 'PT-141' research-chemical form share the molecule, but the research-chemical form sits outside the regulatory framework, with no oversight of identity or purity [9].
What is bremelanotide?
Bremelanotide is the INN for PT-141 — a synthetic cyclic-heptapeptide melanocortin (MC4R/MC3R) agonist [1]. It was approved in the US in 2019 (NDA 210557) as a subcutaneous injection for HSDD in premenopausal women, dosed 1.75 mg as needed [7]. It acts centrally on brain desire circuits, not on blood flow [10].
What is the PT-141 dosage?
The US prescribing information specifies 1.75 mg subcutaneous, as needed, at least 45 minutes before anticipated activity, with a maximum of one dose per 24 hours and no more than 8 doses per month, for the approved HSDD indication [7]. Terminal half-life is ~2.7 h (range 1.9-4.0 h) [7]. This is the labeled dose, not a recommendation.
How much PT-141 should I take?
This site recommends no dose to anyone. For the approved indication, the label specifies 1.75 mg subcutaneous as needed (maximum one dose per 24 hours, 8 per month) for premenopausal women with HSDD [7]. Any use outside that indication, and the research-chemical form, are off-label or unregulated [9]. Dosing decisions are clinical, not editorial.
How much PT-141 to inject?
The labeled subcutaneous dose for the approved HSDD indication is 1.75 mg, as needed, no more than once per 24 hours and 8 times per month [7]. This is documented as a labeled dose for one approved use, not guidance for any reader. The research-chemical form has no verified concentration, so any stated volume is unreliable [9].
What is the PT-141 dosage for women?
For the approved use in premenopausal women with HSDD, the label dose is 1.75 mg subcutaneous as needed [7]. This was the dose tested in the RECONNECT Phase 3 trials (1,267 women), which met their coprimary desire and distress endpoints over 24 weeks [3]. Postmenopausal women are not an approved population.
How do you reconstitute PT-141?
The approved bremelanotide product is supplied as a ready-to-use subcutaneous injection at 1.75 mg, not a powder a patient reconstitutes [7]. Reconstitution questions usually concern the research-chemical form, which is unregulated, of uncertain identity and purity, and outside this site's scope [9]. This is an editorial digest; it gives no preparation instructions.
How do you take PT-141?
The approved drug is given as a subcutaneous injection (under the skin) at 1.75 mg, as needed, at least 45 minutes before anticipated activity, for HSDD in premenopausal women [7]. Other routes — intranasal and intravenous — were studied early; intranasal was discontinued for pharmacokinetic variability [13]. This describes the studied routes, not personal instructions.
How often can you take PT-141?
The label caps the approved use at one 1.75 mg dose per 24 hours and no more than 8 doses per month [7]. In the 52-week open-label extension (684 women), this regimen produced sustained desire improvement with no new safety signals; the most common adverse events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4].